摘要
目的:探讨化疗前后小细胞肺癌(SCLC)患者血清血管内皮生长因子(VEGF)和碱性成纤维细胞生长因子(b-FGF)水平的变化及临床意义。方法:用酶联免疫吸附法测定34例SCLC患者化疗前后VEGF和b-FGF的浓度变化,并与34例健康志愿者做对照。结果:化疗前肺癌组VEGF及b-FGF水平均明显高于健康对照组,差异有统计学意义(P<0.001);化疗后有效组VEGF及b-FGF水平明显低于化疗前,差异有统计学意义(P<0.001);肺癌组VEGF和b-FGF水平无显著相关性;相关性分析表明VEGF浓度的升高仅与化疗疗效和NSE升高相关(P<0.05),b-FGF的升高与各项病理特征均无显著相关性(P>0.05);Kaplan-Meier生存分析证实VEGF和b-FGF低浓度组的平均生存期均明显长于高浓度组(P<0.05)。结论:SCLC患者血清VEGF和b-FGF浓度与生存明显相关,可以作为SCLC患者生存的预后因子。此外,化疗前后血清VEGF和b-FGF浓度变化可以作为预测SCLC患者化疗疗效的指标。
Objective： This study evaluated the changes in the levels of serum vascular endothelial growth factor （VEGF） and b-ftbroblast growth factor （b-FGF） and their clinical significance in patients with small cell lung cancer （SCLC） before and after chemo- therapy. Methods： Serum VEGF and b-FGF were measured in 34 patients with SCLC using ELISA, and the results were compared with measurements from healthy volunteers. Results： A significant difference was found in the serum VEGF and b-FGF levels between the patients with SCLC and the healthy volunteers （P〈0.01）. The serum VEGF and b-FGF levels of the effective treatment group decreased after chemotherapy （P〈0.01）, whereas no significant difference was found in the ineffective treatment group before and after chemotherapy （P〉 0.05）, No statistically significant relationship was found between the serum VEGF and the b-FGF levels. Considering the median con- centration of serum VEGF and b-FGF as a cut-off, the correlation analysis showed that the elevated VEGF level was correlated only with poor efficacy of chemotherapy and the increase in neuron-specific enolase （P〈0.01）. The high b-FGF level has no significant correlation with any pathological characteristic （P〉0.05）. Results from the Kaplan-Meier survival analysis showed that patients with low-level VEGF or b-FGF had significantly longer over-all survival time than those with high-level VEGF or b-FGF （P〈0.01）. Conclusion： Significant correlation was found between the survival of patients with SCLC and the serum VEGF or b-FGF level. Therefore, serum VEGF and b-FGF may be used as prognostic factors for survival and as indicators in predicting the efficacy of chemotherapy in patients with SCLC.
出处
《中国肿瘤临床》
CAS
CSCD
北大核心
2013年第11期638-642,共5页
Chinese Journal of Clinical Oncology
